Insulin in sepsis and septic shock

Journal of Association of Physicians of India

Volumn 51, Issue JUL, 2003, Pages 695-700

  Das, Undurti N ^a,b  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b EFA Sciences LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; INSULIN;

ANIMAL; BLOOD; CARDIOMYOPATHY; HUMAN; INSULIN RESISTANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SEPSIS; SEPTIC SHOCK;

ANIMALS; CARDIOMYOPATHIES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; SEPSIS; SHOCK, SEPTIC;

EID: 2842554886     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Das UN. Critical advances in septicemia and septic shock. Crit Care 2000;4:290-294.
2. Webb S. The role of mediators in septicemia resolution. Adv Septicemia 2002;2:8-14.
3. Abraham E. Why immunomodulatory therapies have not worked in septicemia? Intensive Care Med 1999;25:556-66.
4. Foulds S, Galustian C, Mansfield AO, Schachter M. Transcription factor NFêB expression and posrsurgical organ dysfunction. Ann Surg 2001;233:70-8.
5. Paterson RL, Galley HF, Dhillon JK, Webster NR. Increased nuclear factor êB activation in critically ill patients who die. Crit Care Med 2000;28:1047-51.
6. Bohrer H, Qiu F, Zimmermann T, Zhang Y, Jllmer T, Mannel D, Bottiger BW, Stern DM, Waldherr R, Saeger H-D, Ziegler R, Bierhaus A, Martin E, Nawroth PP. Role of NFêB in the mortality of sepsis. J Clin Invest 1997;100:972-85.
7. Lavon I, Goldberg I, Amit S, Landsman L, Jung S, Tsuberi B-Z, Barshack I, Kopolovic J, Galun E, Bujard H, Ben-Neriah Y. High susceptibility to bacterial infection, but no liver dysfunction, in mice compromised for hepatocyte NF-êB activation. Nature Med 2000;6:573-77.
8. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol 1994;76:5-13.
9. Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L, Lohinai Z, Southan GJ, Salzman AL, Szabo C. Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 2000;164:1013-19.
10. Firestein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A, Sambol B, Mullane KM. Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 1994;152:5853-59.
11. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-êB in the resolution of inflammation. Nature Med 2001;7:1291-97.
12. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA. Inducible cyclo-oxygenase may have antiinflammatory properties. Nature Med 1999;5:698-701.
13. Marchant A, Deviere J, Byl B, DeGroote D, Vincent JL, Goldman M. Interleukin-10 production during septicemia. Lancet 1994;343:707-8.
14. Das UN. Transforming growth factor-beta: Is it an endogenous cardioprotector? Med Sci Res 1993;21:373-5.
15. Lang CH, Dobrescu C. In vivo insulin resistance during nonlethal hypermatebolic sepsis. Circ Shock 1989;28:165-78.
16. Chambrier C, Laville M, Rhzioual Berrada K, Odeon M, Bouletreau P, Beylot M. Insulin sensitivity of glucose and fat metabolism in severe sepsis. Clin Sci (Colch) 2000;99:321-8.
17. Maitra SR, Wojnar MM, Lang CH. Alterations in tissue glucose uptake during the hyperglycemic and hypoglycemic phases of sepsis. Shock 2000;13:379-85.
18. Vary TC, Drnevich D, Jurasinski C, Brennan WA Jr. Mechanisms regulating skeletal muscle glucose metabolism in sepsis. Shock 1995;3:403-10.
19. Lind L, Lithell H. Impaired glucose and lipid metabolism seen in intensive care patients is related to severity of illness and survival. Clin Intensive Care 1994;5:100-5.
20. Fan J, Li YH, Wojnar MM, Lang CH. Endotoxin-induced alterations in insulin-stimulated phosphorylation of insulin receptor, IRS-1, and MAP kinase in skeletal muscle. Shock 1996;6:164-70.
21. Dahn MS, Lange MP, Mitchell RA, Lobdell K, Wilson RF. Insulin production following injury and sepsis. J Trauma 1987;27:1031-38.
22. Raymond RM, Harkema JM, Emerson TE Jr. In vivo skeletal muscle insulin resistance during E coli endotoxin shock in the dog. Circ Shock 1981;8:425-33.
23. Maitra SR, Wang S, Baithwaite CE, El-Maghrabi MR. Alterations in glucose-6-phosphatase gene expression in sepsis. J Trauma 2000;49:38-42.
24. Das UN. Possible beneficial action(s) of glucose-insulinpotassium regimen in acute myocardial infarction and inflammatory conditions: a hypothesis. Diabetologia 2000;43:1081-82.
25. Hinshaw LB, Archer LT, Benjamin B, Bridges C. Effects of glucose or insulin on myocardial performance in endotoxin shock. Proc Soc Exp Biol Med 1976;152:529-34.
26. Archer LT, Beller BK, Drake JK, Whitsett TL, Hinshaw LB. Reversal of myocardial dysfunction in endotoxin shock with insulin. Can J Physiol Pharmacol 1978;56:132-8.
27. Zhu P, Lu L, Xu Y, Greyson C, Schwartz GG. Glucose-insulinpotassium preserves systolic and diastolic function in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 2000;278:H595-603.
28. Mauritz W, Schindler I, Zadrobilek E, Sporn P. Glucosepotassium-insulin in hypodynamic septic shock. Anaesthetist 1986;35:623-27.
29. Bronsveld W, van den Bos GC, Thijs LG. Use of glucoseinsulin-potassium (GIK) in human septic shock. Crit Care Med 1985;13:566-70.
30. Das UN. Insulin: an endogenous cardioprotector. Current Opinion in Critical Care, in press.
31. Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000;355:773-8.
32. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinade P, Lauwers P, Buillon R. Intensive insulin therapy in critically ill. N Engl J Med 2001;345:1359-67.
33. Das UN. Is insulin an endogenous cardioprotector? Crit Care 2002;6:389-93.
34. Christiansen CL, Schurizek BA, Malling B, Knudsen L, Alerti KG, Hermansen K. Insulin treatment of the insulin-dependent diabetic patient undergoing minor surgery. Continuous intravenous infusion compared with subcutaneous administration. Anaesthesia 1988;43:533-7.
35. Das UN. Is insulin an anti-inflammatory molecule? Nutrition 2001;17:409-413.
36. Das UN. Insulin and the critically ill. Crit Care 2002;6:262-3.
37. Diaz R, Paolasso EA, Piegas LS, Tajer CD, Moreno MG, Corvalan R, Isea JE, Romero G. Metabolic modulation of acute myocardial infarction. The ECLA (Estudios Cardiologicos Latinoamerica) Collaborative Group. Circulation 1998;98:2227-34.
38. Van Campen CMC, Klein LJ, Visser FC. Glucose-insulinpotassium imaging: the past and the future? Heart Metabol 2001;12:14-18.
39. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, Rapaport E, Riegel B, Russell RO, Smith EE III, Weaver WD, Gibbons RJ, Alpert JS, Eagle KA, Garner TJ, Garson A Jr, Gregoratos G, Smith SC Jr. 1999 update: ACC/AHA Guidelines for the Management of Patients with Acute Myocardial Infarction: Executive Summary and Recommendations: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation 1999;100:1016-30.
40. Giardino I, Edelstein D, Brownlee M. BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation end products in bovine endothelial cells. J Clin Invest 1996;97:1422-28.
41. Das UN. Free radicals, cytokines and nitric oxide in cardiac failure and myocardial infarction. Mol Cell Biochem 2000;215:145-52.
42. Mohanty P, Hamouda W, Garg R, Aljada A, Ghanim H, Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leukocytes. J Clin Endocrinol Metab 2000;85:2970-73.
43. Booth G, Stalker TJ, Lefer AM, Scalia R. Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin. Am J Physiol 2001;280:E848-56.
44. Aljada A, Ghanim H, Saadesh R, Dandona P. Insulin inhibits NFkB and MCP-1 expression in human aortic endothelial cells. J Clin Endocrinol Metab 2001;86:450-3.
45. Das UN. Insulin and inflammation: further evidence and discussion. Nutrition 2002;18:526-7.
46. Guzik TJ, Mussa S, Gastaldi D, Sadowski J, Ratnatunga C, Pillai R, Channon KM. Mechanisms of increased vascular superoxide production in human diabetes mellitus. Circulation 2002;105:1656-62.
47. Eschke MG, Einspanier R, Klein D, Jauch K-W. Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Medicine 2002;8:443-50.
48. Satomi N, Sakurai A, Haranaka K. Relationship of hypoglycemia to tumor necrosis factor production and antitumor activity: role of glucose, insulin, and macrophages. J Natl Cancer Inst 1985;74:1255-60.
49. Fraker DL, Merino MJ, Norton JA. Reversal of the toxic effects of cachectin by concurrent insulin administration. Am J Physiol 1989;256(6 Pt 1):E725-31.
50. Law WR, McLane MP, Raymond RM. Adenosine restores myocardial responsiveness to insulin during acute endotoxin shock in vivo. Circ Shock 1989;28:333-45.
51. Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D, Reibman J, Li M, Jinag C-K, Hirschhorn R, Recht PA, Ostad E, Levin RI, Cronstein BN. Wound healing is accelerated by agonists if adenosine A2 (Gas-linked) receptors. J Exp Med 1997;186:1615-20.